secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-04-18T23:59:59+00:00
Accession:  0001193125-24-100080
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec reports positive interim clinical data for BB-301 in OPMD first subject at 90 days
--------------------------------------------------------------------------------

- First subject showed improvements in videofluoroscopic swallowing studies and Sydney Swallow Questionnaire at Day 90 vs. pre-dose baseline.
- No serious adverse events observed; two subjects had transient Grade 2 GERD that resolved with standard medication.
- BB-301 is a gene therapy for OPMD, affecting ~15,000 patients worldwide; has FDA and EMA Orphan Drug designation.
- Data from 90-day timepoint demonstrated improvement over initial natural history measurements taken >12 months prior.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524100080/0001193125-24-100080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524100080/d815188d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-100080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer